Oxford BioDynamics - OBD Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 15.55
▲ +0.55 (3.67%)

This chart shows the closing price for OBD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oxford BioDynamics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBD

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Oxford BioDynamics in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 15.55.

This chart shows the closing price for OBD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Oxford BioDynamics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/24/2023Shore CapitalReiterated RatingHouse Stock
9/12/2022Shore CapitalReiterated RatingHouse Stock
6/28/2022Shore CapitalReiterated RatingHouse Stock
2/25/2022Shore CapitalReiterated RatingHouse Stock
1/25/2022Shore CapitalReiterated RatingHouse Stock
10/28/2021Shore CapitalReiterated RatingHouse Stock
6/15/2021Shore CapitalReiterated RatingHouse Stock
6/16/2020Shore CapitalReiterated RatingHouse Stock
10/25/2019Shore CapitalReiterated RatingHouse Stock
(Data available from 1/29/2018 forward)

News Sentiment Rating

-0.60 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/31/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Oxford BioDynamics logo
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: GBX 15.55
Low: 14.75
High: 15.74

50 Day Range

MA: GBX 17.74
Low: 13.65
High: 21.38

52 Week Range

Now: GBX 15.55
Low: 10.98
High: 33

Volume

454,169 shs

Average Volume

150,668 shs

Market Capitalization

£22.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Oxford BioDynamics?

The following equities research analysts have issued reports on Oxford BioDynamics in the last twelve months: Shore Capital.
View the latest analyst ratings for OBD.

What is the current price target for Oxford BioDynamics?

0 Wall Street analysts have set twelve-month price targets for Oxford BioDynamics in the last year. has the lowest price target set, forecasting a price of £100,000 for Oxford BioDynamics in the next year.
View the latest price targets for OBD.

What is the current consensus analyst rating for Oxford BioDynamics?

Oxford BioDynamics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OBD.

What other companies compete with Oxford BioDynamics?

How do I contact Oxford BioDynamics' investor relations team?

Oxford BioDynamics' physical mailing address is 26 Beaumont Street, OXFORD, OX1 2NP, United Kingdom. The biotechnology company's listed phone number is +44-1865-518910. The official website for Oxford BioDynamics is www.oxfordbiodynamics.com. Learn More about contacing Oxford BioDynamics investor relations.